Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data.

Angelo FassioDavide GattiDavide BertelleElena FracassiGiulia ZanettiOmbretta ViapianaMaurizio Rossini Giovanni Adami

Published in: Therapeutic advances in musculoskeletal disease (2022)

The present data seem to suggest that AIIRDs do not represent a risk factor for denosumab discontinuation. Furthermore, the presence of AIIRDs does not seem to impair its effectiveness in terms of BMD.

Keyphrases

bone mineral density
postmenopausal women
body composition
electronic health record
big data
randomized controlled trial
systematic review
multiple sclerosis
oxidative stress
combination therapy
data analysis
drug induced